RESOLVE-IT Failure Dashes Genfit's NASH Hopes

Elafibranor Missed Trial Endpoints At The Interim Stage

 
• By Sten Stovall

Genfit SA is now pinning its hopes for elafibranor on primary biliary cholangitis after the dual PPAR alpha/delta agonist failed in its Phase III RESOLVE-IT trial for NASH.

Target
RESOLVE-IT missed its primary endpoint for treating NASH • Source: Shutterstock

More from Clinical Trials

More from R&D